NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquir ...

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”). If you wish to serve as lead plaintiff, you must move th ...

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a co ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategyWALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings signi ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation Details - The investigation is focused on Zenas BioPharma, Inc. (NASDAQ: ZBIO) regarding possible misleading information that may have affected investors [1]. - Shareholders who purchased Zenas BioPharma securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. Group 2: Class Action Information - Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Zenas BioPharma [2]. - Interested parties can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling significant cases [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation Details - The investigation is focused on Zenas BioPharma, Inc. (NASDAQ: ZBIO) regarding possible misleading information that may have affected investors [1]. - Shareholders who purchased Zenas BioPharma securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket fees or costs [2]. Group 2: Class Action Information - Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Zenas BioPharma [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].

–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa vo ...

Financial Performance - As of December 31, 2024, the total assets of Zenas BioPharma, Inc. increased to $369.968 million from $68.180 million in 2023, representing a growth of approximately 442%[753] - Total revenue for 2024 was $5,000, a significant decrease of 90% compared to $50,000 in 2023[754] - The net loss attributable to common stockholders increased to $156,988 in 2024, compared to a loss of $37,124 in 2023, reflecting a 323% increase in losses[754] - The Company reported a comprehensive loss of $156,831 in 2024, compared to a comprehensive loss of $37,046 in 2023[754] - The Company incurred significant operating losses and negative cash flows since inception, with expectations for continued losses in the foreseeable future[766] - The Company reported a net loss attributable to common stockholders for the years ended December 31, 2024, and 2023[821] - The Company incurred a segment net loss of $157.0 million in 2024, compared to a net loss of $37.1 million in 2023, reflecting a 323% increase in losses[934] Cash and Liquidity - Cash and cash equivalents rose significantly to $319.742 million in 2024, compared to $56.857 million in 2023, indicating a growth of about 463%[753] - Cash, cash equivalents, and restricted cash at the end of 2024 totaled $319,832, a substantial increase from $56,943 at the end of 2023[759] - The Company experienced a net increase in cash of $262,889 in 2024, contrasting with a decrease of $10,352 in 2023[759] - As of December 31, 2024, the Company had cash, cash equivalents, and short-term investments totaling $350.8 million, expected to fund operations for at least twelve months[768] Expenses and Liabilities - The total current liabilities increased to $57.292 million in 2024 from $23.258 million in 2023, reflecting a rise of approximately 146%[753] - The accumulated deficit expanded to $(387.391) million in 2024, up from $(230.403) million in 2023, marking an increase of about 68%[753] - Research and development expenses surged to $139,139 in 2024, up 132% from $60,033 in 2023[754] - Stock-based compensation expense rose to $10,821 in 2024, up from $3,495 in 2023, marking a 210% increase[759] - Total accrued expenses increased to $39.4 million as of December 31, 2024, up from $17.3 million in 2023, primarily due to external research and development expenses[837] Financing and Capital Structure - Zenas BioPharma anticipates substantial additional financing will be required to achieve its goals, with potential dilution to stockholders if capital is raised[12] - The Company completed its IPO on September 16, 2024, raising $258.7 million in gross proceeds from the sale of 15,220,588 shares at $17.00 per share, with net proceeds of $234.3 million after expenses[764] - Proceeds from the issuance of Series C convertible preferred stock amounted to $178,381 in 2024, with no such proceeds reported in 2023[759] - The convertible preferred stock converted into common stock upon the completion of the Company's IPO on September 16, 2024[816] Research and Development - The Company is focused on developing immunology-based therapies for autoimmune and rare diseases, with several product candidates in development[761] - The Company has a single reportable segment dedicated to the research and development of precision immunology-based therapies[775] - Direct research and development expenses for Obexelimab reached $94.6 million in 2024, compared to $25.4 million in 2023, indicating a 272% increase[934] Agreements and Collaborations - The Company entered into a license agreement with Viridian Therapeutics, Inc. for exclusive rights to develop and commercialize certain antibody product candidates, with an initial consideration of 38,707 shares of common stock[873] - The Company entered into a license agreement with Zai Lab on January 24, 2025, receiving an upfront fee of $10.0 million and potential future milestones of up to $96.0 million[937] - The Company entered into a novation agreement with Tenacia, transferring its rights and obligations under the Dianthus Agreements[852] Tax and Deferred Assets - The effective income tax rate for the year ended December 31, 2024, was (0.3)%, a decrease from (0.8)% in 2023, primarily due to changes in income earned in the U.S.[912] - The valuation allowance against deferred tax assets increased by $50.5 million from December 31, 2023, to December 31, 2024, primarily due to additional net operating losses[914] - The Company had approximately $75.5 million in federal net operating loss carryforwards and $65.0 million in state net operating loss carryforwards as of December 31, 2024[916] Market and Competition - Zenas BioPharma faces competition from established pharmaceutical and biotechnology companies that have made significant investments in novel treatments for immunological indications[12] - The complexity of manufacturing product candidates may lead to delays or difficulties in production, impacting clinical trial supply and marketing approval[12] Personnel and Management - The company is dependent on retaining key personnel and may face challenges in managing growth and expanding operations[12]